

# Contents

	Page No.
<b>Introduction</b>	1
<b>Aim of the work</b>	2
<b>Review of literature</b>	3
• Definition of stem cell	3
• Types of Stem cells	4
• Regenerative cell therapy	10
• Haematopietic stem cells, properties and haemopoiesis	16
• Haematopoietic stem cell transplantation	26
• Complications of stem cell transplantation.	58
• Non myeloablative stem cell transplantation	93
• Concept of quality of life	99
<b>Subjects and Methods</b>	110
<b>Results</b>	124
<b>Discussion</b>	156
<b>Summary and Conclusion</b>	196
<b>Recommendation</b>	198
<b>Annex</b>	2001
<b>References</b>	211
المخلص العربي	١

## List of Tables

<b>Table</b>	<b>No.</b>
<b>Table (1): Main characteristics of the five best-known hematopoietic growth factors (colony-forming substances).</b>	<b>18</b>
<b>Table (2): Basic immunophenotype of haemopoietic stem cells</b>	<b>24</b>
<b>Table (3): Differentiation of pluripotential stem cells during haematopoiesis</b>	<b>25</b>
<b>Table (4): Changes in properties of hematopoietic cells during differentiation.</b>	<b>25</b>
<b>Table (5): Factors influencing the choice of allogeneic donor</b>	<b>39</b>
<b>Table (6): Factors influencing the success of autologous donation</b>	<b>39</b>
<b>Table (7): Factors affecting mobilization of (PBPC)</b>	<b>41</b>
<b>Table (8): Factors affecting the speed of engraftment by (PBPC)</b>	<b>41</b>
<b>Table (9): Popular preparative regimens for common transplant indications</b>	<b>54</b>
<b>Table (10): HLA- identical matched sibling allogeneic stem cell transplantation 5- years disease free survival (DFS)</b>	<b>57</b>
<b>Table (11): Clinical manifestations and stages of Acute GVHD</b>	<b>64</b>
<b>Table (12): Histologic grades of acute GVHD</b>	<b>65</b>
<b>Table (13): Prophylaxis of Graft Versus Host Disease</b>	<b>65</b>
<b>Table (14): Comparison of acute &amp; chronic GVHD</b>	<b>67</b>
<b>Table (15): The recommended vaccination after BMT</b>	<b>69</b>
<b>Table (16): Causes of abnormal liver function tests after allogeneic</b>	<b>77</b>
<b>Table (17): Common delayed complications after allogeneic SCT.</b>	<b>83</b>
<b>Table (18): Classification of chronic GVHD</b>	<b>85</b>
<b>Table (19): Advantages/disadvantages of reduced-intensity conditioning</b>	<b>95</b>
<b>Table (20): Facets incorporated within the WHO QOL-BREF domains</b>	<b>109</b>

## List of Figures

<i>Figure</i>		<i>No.</i>
<b>Figure (1):</b>	Stem cell potentials	<b>3</b>
<b>Figure (2):</b>	Human stem cells	<b>4</b>
<b>Figure (3):</b>	Promise of stem cell research	<b>15</b>
<b>Figure (4):</b>	Haematopoietic Stem cell	<b>16</b>
<b>Figure (5):</b>	Stages in haemopoietic cell development	<b>17</b>
<b>Figure (6):</b>	Haemopoietic stem cell and marrow stromal cell plasticity	<b>19</b>
<b>Figure (7):</b>	Stages in homing and mobilization of stem cells	<b>23</b>
<b>Figure (8):</b>	Peripheral blood stem cell	<b>31</b>
<b>Figure (9):</b>	Somatic cell nuclear transfer	<b>49</b>
<b>Figure (10):</b>	Typical haematological chart of a patient undergoing allogeneic marrow transplantation for aplastic anaemia.	<b>56</b>
<b>Figure (11):</b>	Infectious complications after allogeneic SCT.	<b>68</b>

## List of Results

<b>Table and figure No.</b>	<b>Description</b>	<b>Page No.</b>
<b>Table (1):</b>	<b>Frequency distribution of the studied group according to allogeneic &amp; autologous recipients</b>	<b>124</b>
<b>Table (2):</b>	<b>Gender of the patient</b>	<b>125</b>
<b>Table (3):</b>	<b>Social standard of the patients</b>	<b>125</b>
<b>Table (4):</b>	<b>Degree of complications</b>	<b>126</b>
<b>Table (5):</b>	<b>Frequency distribution of the allogeneic stem-cell recipients according to gender</b>	<b>127</b>
<b>Table (6):</b>	<b>Different indications of stem-cell transplantation among allogeneic group</b>	<b>127</b>
<b>Table (7):</b>	<b>Distribution of allogeneic group according to graft rejection</b>	<b>128</b>
<b>Table (8):</b>	<b>Distribution of allogeneic group according to graft versus host disease</b>	<b>128</b>
<b>Table (9):</b>	<b>Distribution of allogeneic group according to presence of infection</b>	<b>129</b>
<b>Table (10):</b>	<b>Different patterns of encountered infections among allogeneic group</b>	<b>129</b>
<b>Table (11):</b>	<b>Different patterns of encountered infections according to time of documentation of infection</b>	<b>130</b>
<b>Table (12):</b>	<b>Frequency distribution of the allogeneic stem-cell recipients according to presence of organ toxicity</b>	<b>130</b>
<b>Table (13):</b>	<b>Frequency distribution of the allogeneic stem-cell recipients according to type of organ toxicity</b>	<b>131</b>
<b>Table (14):</b>	<b>Distribution of allogeneic group according to ICU support</b>	<b>131</b>
<b>Table (15):</b>	<b>Frequency distribution of autoimmunity among allogeneic group</b>	<b>132</b>
<b>Table (16):</b>	<b>Frequency distribution of growth affection among allogeneic group</b>	<b>132</b>
<b>Table (17):</b>	<b>Frequency distribution of autologus group according to gender</b>	<b>133</b>

<b>Table (18):</b>	<b>Frequency distribution of autologus group according to social class</b>	<b>133</b>
<b>Table (19):</b>	<b>Frequency distribution of autologus group according to degree of Complications</b>	<b>134</b>
<b>Table (20):</b>	<b>Frequency distribution of autologus group according to graft rejection</b>	<b>134</b>
<b>Table (21):</b>	<b>Frequency distribution of autologus group according to presence of infection</b>	<b>135</b>
<b>Table (22):</b>	<b>Infections patterns encountered in autologous group</b>	<b>136</b>
<b>Table (23):</b>	<b>Time of documentation of infections in different patterns</b>	<b>137</b>
<b>Table (24):</b>	<b>Frequency distribution of autologus group according to presence of organ toxicity</b>	<b>138</b>
<b>Table (25):</b>	<b>Distribution of autologous group according to occurrence of toxicities in different organs.</b>	<b>139</b>
<b>Table (26):</b>	<b>Frequency distribution of autologus group according to presence of ICU Support</b>	<b>140</b>
<b>Table (27):</b>	<b>Frequency distribution of autologus group according to presence of relapse</b>	<b>140</b>
<b>Table (28):</b>	<b>Relation between type of procedure and degree of complication</b>	<b>141</b>
<b>Table (29):</b>	<b>Relation between type of procedure and presence of infection</b>	<b>142</b>
<b>Table (30):</b>	<b>Relation between type of procedure and presence of organ Toxicity.</b>	<b>143</b>
<b>Table (31):</b>	<b>Relation between type of procedure and presence of graft rejection</b>	<b>144</b>
<b>Table (32):</b>	<b>Relation between type of procedure and graft versus host Disease</b>	<b>145</b>
<b>Table (33):</b>	<b>Relation between type of procedure and ICU support</b>	<b>146</b>
<b>Table (34):</b>	<b>Relation between initial disease and current situation</b>	<b>147</b>
<b>Table (35):</b>	<b>Relation between the type of procedure and the patient's viability</b>	<b>148</b>
<b>Table (36):</b>	<b>Relation between initial disease and relapse</b>	<b>149</b>
<b>Table (37):</b>	<b>Frequency distribution of child QOL score according to different levels</b>	<b>150</b>
<b>Table (38):</b>	<b>Frequency distribution of parent QOL score according to different social levels</b>	<b>151</b>
<b>Table (39):</b>	<b>Mean and standard deviation of QOL at different levels of social standards for both child &amp; parents</b>	<b>152</b>
<b>Table (40):</b>	<b>Means and standard deviations of QOL of both child and parents</b>	<b>153</b>

	<b>according to degree of complications</b>	
<b>Table (41):</b>	<b>Relation between initial disease and child QOL</b>	<b>154</b>
<b>Table (42):</b>	<b>Relation between initial disease and parent QOL</b>	<b>154</b>
<b>Table (43):</b>	<b>Relation between type of procedure and child QOL</b>	<b>155</b>
<b>Table (44):</b>	<b>Relation between type of procedure and parent QOL</b>	<b>155</b>